After 12 months of follow-up, the patient was treated with maximal tolerated doses of renin-angiotensin system inhibitors combined with Nefecon, the patient’s urine protein decreased significantly and renal function was stable, and no hematological disorders were found during the follow-up. The gene discussed is REN; the disease is hematologic disorder.